Search
2025
2024
2023
-
Nov 19, 2025
YolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1)Read More
-
Sep 11, 2025
YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICCRead More
-
Jul 28, 2025
YOLT-203 Receives Orphan Drug Designation from EMARead More
-
Jul 14, 2025
YolTech Therapeutics Announces NMPA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)Read More
-
Jun 27, 2025
Prof. Michael Ott Joins YolTech as Scientific AdvisorRead More
